Tak 700 SWOG 1216 overall survival 81 months is this correct.
Of it is why is it not being talked about used deployed more ?
Can anyone enlighten me ?
Thank you in advance
Why is Tak 700 not being used when tr... - Advanced Prostate...
Why is Tak 700 not being used when trials showed such great results ?
Written by
Farn
To view profiles and participate in discussions please or .
19 Replies
•
You seem to have misunderstood. TAK 700 failed to show that it extended survival any better than a placebo. It failed before or after docetaxel.
ncbi.nlm.nih.gov/labs/pmc/a...
thelancet.com/journals/lano...
cancertherapyadvisor.com/ho...
Hi am I misinterpreting this report the figure 81 months jumps off the page but have I got excited about a different type of prostate cancer ?
There was no survival benefit. BOTH the treatment and control group had higher-than-expected survival. That often happens in clinical trials because all participating patients get such excellent medical attention.
The 81 months median OS with TAK-700 was a very pleasant surprise, and it apparently means that the new treatments available at later stages (CRPC) are adding a couple of years to survival in general.
The 81 months median OS was almost statistically superior to the 70 months OS for the casodex control arm, which was also much larger than expected. The study author says “Obviously, not surprising, the SWOG 1216 trial has the highest overall survival of the control arm ever reported, ever, in the history of prostate cancer medicine.” He also says “SWOG 1216 has the highest number of patients who received a subsequent life-prolonging post-protocol therapy.” He concludes “it speaks about the access of these life-prolonging therapies approved in castrate-resistant prostate cancer setting to our patients in SWOG 1216.”
(The quotes are from an interview with the principal investigator on the study, Neeraj Agarwal at urotoday.com/categories-med... )
Tak-700 is a cyp-17a inhibitor, just like abiraterone (cyp-17a is an enzyme the body needs to make testosterone), so they are similar. In fact, the long term median Os for abiraterone from the stampede trial was 6.6 years, which is 79.2 months, which is similar to Tak-700’s 81 months, so a patient should get similar results with either drug.
do we know he would not have had good luck without it?
A quick search found this informative info; 'orteronel' is the base name of Tak 700. This site gives a synopsis of the trial(s) and explains why the stage 3 trials were canceled.
Where's LuLu when we need him.... Probably taking a de-stuttering course since his real UserId is Lu.......
Good Luck, Good Health and Good Humor.
j-o-h-n Monday 01/31/2022 6:36 PM EST
in reply to j-o-h-n
Hoo -who ? Me . Im just a gigolo, life goes on without Me!
Thanks Nal .
Dam! I’m at 80 months now!😳
Amen brother🙏
Not what you're looking for?
You may also like...
VISION Trial Results Being Released
Median overall survival was 15.3 months for patients in the 177Lu-PSMA-617 arm vs. 11.3 months in...
